DailySand tracks Amgen across AI, semiconductor infrastructure, capital markets, and critical minerals supply chains. Below are curated source items and daily digests where Amgen appears in today's cross-sector intelligence briefing.
1 item across 1 digest
Novartis, Amgen and Eli Lilly are developing drugs targeting a specific form of cholesterol to create the next blockbuster cardiology treatments. This represents a major pharmaceutical investment shift toward precision cardiovascular medicine that could reshape the $50+ billion heart disease drug market.
Read original →
DailySand